AWM Investment Company Inc. Has $1.85 Million Position in OncoCyte Co. (NASDAQ:OCX)

AWM Investment Company Inc. lessened its holdings in shares of OncoCyte Co. (NASDAQ:OCX - Free Report) by 29.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 775,804 shares of the company's stock after selling 321,371 shares during the period. AWM Investment Company Inc. owned approximately 4.61% of OncoCyte worth $1,846,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of OCX. Ground Swell Capital LLC bought a new position in OncoCyte in the fourth quarter valued at approximately $26,000. Two Sigma Securities LLC acquired a new position in OncoCyte in the 4th quarter worth $31,000. Geode Capital Management LLC increased its holdings in OncoCyte by 31.8% during the 4th quarter. Geode Capital Management LLC now owns 137,069 shares of the company's stock worth $326,000 after purchasing an additional 33,089 shares in the last quarter. Pura Vida Investments LLC raised its stake in shares of OncoCyte by 32.1% in the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company's stock valued at $1,558,000 after purchasing an additional 159,106 shares during the period. Finally, Broadwood Capital Inc. raised its stake in shares of OncoCyte by 26.7% in the 4th quarter. Broadwood Capital Inc. now owns 6,244,405 shares of the company's stock valued at $14,862,000 after purchasing an additional 1,315,339 shares during the period. 55.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on OCX. Lake Street Capital began coverage on OncoCyte in a report on Friday, March 28th. They set a "buy" rating and a $5.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $4.25 price target on shares of OncoCyte in a research note on Tuesday, May 13th. StockNews.com assumed coverage on shares of OncoCyte in a report on Sunday, April 6th. They issued a "sell" rating on the stock. Finally, Stephens restated an "equal weight" rating and set a $4.00 target price on shares of OncoCyte in a report on Tuesday, March 25th.

OncoCyte Stock Performance

Shares of NASDAQ OCX opened at $2.94 on Wednesday. The stock has a market capitalization of $84.08 million, a PE ratio of -0.83 and a beta of 0.95. OncoCyte Co. has a 52 week low of $1.92 and a 52 week high of $4.75. The stock has a 50 day moving average price of $3.02 and a 200 day moving average price of $2.69.

OncoCyte (NASDAQ:OCX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $2.14 million during the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. As a group, research analysts forecast that OncoCyte Co. will post -2.57 EPS for the current year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Want to see what other hedge funds are holding OCX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoCyte Co. (NASDAQ:OCX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.